This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
More innovative medicines have a shorter assessment time by the CT ASMR rating achieved vs. average time from EMA approval to outcome of CT assessment Key...
The COVID-19 pandemic highlighted global inequities in access to health innovation, and in low- and middle-income countries (LMICs) these inequities are...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...
CRA is a proud sponsor of the event. Kaitlyn Austin presents the session titled “Securing Insight Alignment to Drive Future-Proofed Strategies and...
